866-997-4948(US-Canada Toll Free)

EpiCast Report: Alzheimers Disease - Epidemiology Forecast to 2022

Published By :

GlobalData

Published Date : Feb 2013

Category :

Neurology Devices

No. of Pages : 42 Pages


EpiCast Report: Alzheimers Disease Epidemiology Forecast to 2022

Summary

Alzheimers disease is the most common cause of dementia in people age 60 years and older and accounts for approximately 75% of the total dementia cases worldwide (Qui et al., 2009). The global prevalence of dementia is estimated to be 3.9% in people age 60 years and older, with an overall Alzheimers disease prevalence of 9.7% in the US, 4.4% in Europe, and3.4%in developing countries (Kalaria et al., 2008; Lobo et al., 2000; Plassman et al., 2007). An explosive increase in the number of prevalent cases of Alzheimers disease in all nine markets is expected during the forecast period. GlobalData epidemiologists forecast that prevalent cases of Alzheimers disease In the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India) are expected to increase from 12.53 million cases in 2012 to 16.72 million cases in 2022 with an annual growth rate (AGR) of 3.35%. The global burden of the disease is expected to increase due to rapidly aging populations in different parts of the world. Currently, there is no cure for Alzheimers disease (Mayo Clinic, 2013). Due to the progressive nature of Alzheimers disease, along with the aging world population, there will be a significant demand for care of persons affected with the disease.

Scope

  • The Alzheimers disease EpiCast Report provides an overview of the risk factors and comorbidities associated with Alzheimers disease, as well as global trends in prevalence in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to emerging marketsChina and India).
  • It also includes a 10-year epidemiological forecast of prevalent cases of Alzheimers segmented by sex and age (segmented by five-year age groups, beginning at age 60 years and ending at =90 years).

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global Alzheimers disease market. 
  • Quantify patient populations in the global Alzheimers disease market to improve product development, pricing, and launch plans. 
  • Organize sales and marketing efforts by identifying gender and age groups that present the best opportunities for Alzheimers therapeutics in each of the markets covered.
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7

3 Epidemiology 8
3.1 Risk Factors and Comorbidities 8
3.1.1 Family history of Alzheimer’s disease increases risk by 7.5 times 9
3.1.2 APOE 4 allele triples the risk of Alzheimer’s disease 9
3.1.3 Cardiovascular risk factors increase the risk of Alzheimer’s disease by twofold 9
3.1.4 Incidence and prevalence of Alzheimer’s disease double every five years after age 65 10
3.1.5 Diabetes doubles the risk of Alzheimer’s in men, but only marginally increases the risk in women 10
3.1.6 Women are 1.5 times more likely to develop Alzheimer’s disease than men 11
3.1.7 Mild Cognitive Impairment (MCI) increases the risk of Alzheimer’s disease, but may be part of the causal pathway 11
3.1.8 Depression triples risk of Alzheimer’s disease and is the most common comorbidity 12
3.1.9 Up to 70% of Alzheimer’s disease patients also suffer from anxiety 12
3.1.10 Psychosis and agitation are common comorbidities among Alzheimer’s patients 13
3.2 Global Trends 13
3.2.1 United States 14
3.2.2 5EU 14
3.2.3 Japan 15
3.2.4 China 15
3.2.5 India 15
3.3 Forecast Methodology 16
3.3.1 Sources Used 17
3.3.2 Forecast Assumptions and Methods 21
3.3.3 Sources Not Used 23
3.4 Epidemiology Forecast (2012–2022) 23
3.4.1 Prevalent Cases of Alzheimer’s Disease 23
3.4.2 Age-Specific Prevalent Cases of Alzheimer’s Disease 25
3.4.3 Sex-Specific Prevalent Cases of Alzheimer’s Disease 26
3.4.4 Age-Standardized Prevalence of Alzheimer’s Disease 28
3.5 Discussion 29
3.5.1 Conclusions Regarding Epidemiological Trends 29
3.5.2 Limitations of the Analysis 31
3.5.3 Strengths of the Analysis 31

4 Appendix 32
4.1 Bibliography 32
4.2 About the Authors 37
4.2.1 Epidemiologists 37
4.2.2 Reviewers 38
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 39
4.2.4 Global Head of Healthcare 40
4.3 About GlobalData 41
4.4 About EpiCast 41
4.5 Contact Us 41
4.6 Disclaimer 42

List of Table


Table 1: Risk Factors and Comorbidities for Alzheimers Disease 8
Table 2: DSM III-R Criteria for the Diagnosis of Dementia 16
Table 3: NINCDS-ADRDA Criteria for the Diagnosis of Alzheimers Disease 17
Table 4: Sources of Epidemiological Data Used for the Forecast 18
Table 5: All Markets, Prevalent Cases of Alzheimers Disease, Ages

List of Chart


Figure 1: All Markets, Prevalent Cases (N) of Alzheimers Disease, Ages

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *